Date: July 2024
The RACGP has provided feedback on MSAC application 1752 Anal human papillomavirus (HPV) and cytology testing in high-risk populations to determine access to high-resolution anoscopy and ablative treatment to prevent anal cancer.
The RACGP supports application 1752, which allows GPs to collect the initial anal swab samples from at-risk populations. We recommend remuneration for Category 1 – Professional attendances would be more appropriate to set this fee at the equivalent of a level B consultation.
Read the submission
RACGP response - MSAC 1752 Anal human papillomavirus (HPV) and cytology testing (PDF)